Izotropic Africa Launches Operations in Casablanca

• Izotropic Corporation officially launched "Izotropic Africa" in Casablanca, Morocco on April 29, 2026.
• A regional headquarters was established to manage operations across 38 African countries and the GCC region.
• Mr. Mohammed Sair appointed as General Manager to lead market deployment and regulatory engagement.
• Plans include localized manufacturing/assembly in Morocco and pursuing CE Mark approval for IzoView Breast CT system.
• Sales projections: 40 units Year 1, cumulative 300 units by Year 5 post-regulatory approval.
• The deadline to finalize the Formal Agreement between Izotropic and Izotropic Africa was extended to June 30, 2026 (previously April 30).
• Lease for headquarters executed; focus on regulatory documentation, training, and hospital group engagement.

• Progress vs. Expectations: The launch confirms execution of the strategy announced in February 2026 regarding the Izotropic Africa joint venture. However, the extension of the Formal Agreement deadline from April 30 to June 30 indicates potential friction or delays in finalizing the corporate structure despite operational activities beginning.
• Financial Impact: No immediate revenue recognition is guaranteed; projections are speculative (Year 1 sales). The company recently settled $100k principal debt via equity issuance, reducing cash burden but increasing dilution.
• Market Reaction Context: Price data shows a recovery from February lows ($0.19) to current levels ($0.33), suggesting the market has already priced in the financing and JV news. The April 29 update is largely confirmatory rather than transformative.
• Risk Assessment: The delay in finalizing the Formal Agreement (June 30 vs April 30) introduces execution risk regarding the 40% ownership stake and profit repatriation, which could impact future cash flow visibility.

• Company: Izotropic Corporation (Ticker: IZO).
• Flagship Product: IzoView Breast CT Imaging System.
• Technology: Advanced breast imaging designed to address delayed diagnosis mortality rates in developing regions.
• Strategic Focus: Expansion into Africa and GCC markets via "Izotropic Africa" subsidiary based in Casablanca, Morocco.
• Market Opportunity: Projected addressable market for advanced imaging/oncology devices in Africa exceeds $500 million by 2030; breast cancer leading cause of cancer death among African women (~200k cases annually).